A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

March 11, 2023

Conditions

Unresectable Solid TumorMetastatic Solid TumorLocally Advanced Solid Tumor

Interventions

DRUG

RC118 for injection

RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.

Trial Locations (4)

Remegen Site #12, Macquarie Park

Remegen Site #11, Malvern

Remegen Site #13, Frankston

Remegen Site #14, Bedford Park

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT04914117 - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter